Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Evi Bakirtzi"'
Autor:
Michael Dickinson, Brandon E. Kremer, Arindam Dhar, Thierry Horner, Shawn W. Foley, Michael T. McCabe, Natalie O. Karpinich, Geraldine Ferron-Brady, Evi Bakirtzi, Olena Barbash, Anu Shilpa Krishnatry, Anastasia Wyce, Paolo Gallipoli, Ludovica Marando, Faisal Basheer, Regina García Delgado, Paul Yeh, Natalia Tovar, Maria-Victoria Mateos, Manali Kamdar, Jacob L. Glass, Gareth J. Morgan, Faith E. Davies, Daniel A. Pollyea, Dan T. Vogl, Aristeidis Chaidos, Adrian Alegre, Anastasios Karadimitris, Brian J.P. Huntly, Gautam Borthakur, Mark A. Dawson
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::634832d4a4352226ded7a6d727fa619e
https://doi.org/10.1158/1078-0432.22490779
https://doi.org/10.1158/1078-0432.22490779
Autor:
Michael Dickinson, Brandon E. Kremer, Arindam Dhar, Thierry Horner, Shawn W. Foley, Michael T. McCabe, Natalie O. Karpinich, Geraldine Ferron-Brady, Evi Bakirtzi, Olena Barbash, Anu Shilpa Krishnatry, Anastasia Wyce, Paolo Gallipoli, Ludovica Marando, Faisal Basheer, Regina García Delgado, Paul Yeh, Natalia Tovar, Maria-Victoria Mateos, Manali Kamdar, Jacob L. Glass, Gareth J. Morgan, Faith E. Davies, Daniel A. Pollyea, Dan T. Vogl, Aristeidis Chaidos, Adrian Alegre, Anastasios Karadimitris, Brian J.P. Huntly, Gautam Borthakur, Mark A. Dawson
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological maligna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b56a0a4932aa41df4a01b11e3217650
https://doi.org/10.1158/1078-0432.c.6533218.v1
https://doi.org/10.1158/1078-0432.c.6533218.v1
Autor:
Mark A. Dawson, Gautam Borthakur, Brian J.P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria-Victoria Mateos, Natalia Tovar, Paul Yeh, Regina García Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
Purpose:Molibresib is a selective, small molecule inhibitor of the bromodomain and extra-terminal (BET) protein family. This was an open-label, two-part, Phase I/II study investigating molibresib monotherapy for the treatment of hematological maligna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bebb86f092b88d6bc3976f8b349b6b15
https://pubmed.ncbi.nlm.nih.gov/36350312
https://pubmed.ncbi.nlm.nih.gov/36350312
